Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme presented as a solution for injection for intravenous use. It is employed as an antidote to treat acute intermittent porphyria attacks and other acute hepatic porphyria episodes in affected patients.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics where required. Clients benefit from regulatory support, batch traceability, and timely delivery to clinical sites.

Normosang is used in the management of acute hepatic porphyria by supplying exogenous heme to modulate the porphyrin synthesis pathway. - Acute intermittent porphyria attacks: reduces neurotoxic precursor accumulation and alleviates acute symptoms. - Other acute hepatic porphyria attacks: provides rapid control of biochemical disturbances during crises. - Acute porphyria crises (general): restores heme levels to interrupt the pathogenic cascade.

Normosang may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion site pain or phlebitis. - Fever or chills. - Nausea or vomiting. - Headache. - Transient hypertension. - Mild abdominal discomfort.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Acute hemolysis. - Renal failure or acute kidney injury. - Coagulopathy or thrombosis. - Severe hypotension. - Hepatic dysfunction.

Before using Normosang, clinicians should consider several safety measures. - Monitor liver function: assess hepatic enzymes and bilirubin levels. - Assess renal function: evaluate creatinine and urine output. - Caution in iron overload: avoid concurrent high‑dose iron therapy. - Avoid in patients with known hypersensitivity to hemin or its excipients. - Evaluate porphyria type: confirm indication for acute hepatic attacks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines that affect porphyrin metabolism or coagulation.

Major Interactions (Avoid): - Phenobarbital and other enzyme‑inducing anticonvulsants: may exacerbate porphyrin accumulation. - Sulfonamide antibiotics: can trigger porphyria attacks. - Oral contraceptives containing estrogen: may increase attack frequency.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., heparin): heightened risk of thrombosis. - Iron supplements: risk of iron overload. - Other heme‑containing products: cumulative heme load may affect safety.